NASDAQ : CRNX
Crinetics Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 84.95 USD (At close: Aug 31, 2026) · Market cap 9.01B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 9.01B |
| Enterprise Value | 7.85B |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 106.07M |
| Shares Outstanding | 106.07M |
| Shares Change (YoY) | +11.25% |
| Shares Change (QoQ) | +1.40% |
| Owned by Insiders (%) | 1.49% |
| Owned by Institutions (%) | 96.37% |
| Float | 95.50M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 213.74 |
| Forward PS | 77.26 |
| PB Ratio | 7.54 |
| P/TBV Ratio | 7.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 186.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 15.57 |
| Quick Ratio | 15.24 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -42.45% |
| Return on Assets (ROA) | -26.28% |
| Return on Invested Capital (ROIC) | -27.89% |
| Return on Capital Employed (ROCE) | -44.21% |
| Weighted Average Cost of Capital (WACC) | 4.69% |
| Revenue Per Employee | $70,970 |
| Profits Per Employee | -$844,455 |
| Employee Count | 594 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 180,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.09 |
| 52-Week Price Change | +174.12% |
| 50-Day Moving Average | 74.84 |
| 200-Day Moving Average | 50.44 |
| Relative Strength Index (RSI) | 89.79 |
| Average Volume (20 Days) | 2,566,460 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6.59M |
| Short Previous Month | 5.87M |
| Short % of Shares Out | 6.21% |
| Short % of Float | 6.90% |
| Short Ratio (days to cover) | 2.26 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 42.16M |
| Gross Profit | -334.72M |
| Operating Income | -549.09M |
| Pretax Income | -501.43M |
| Net Income | -501.61M |
| EBITDA | -544.85M |
| EBIT | -549.09M |
| Loss Per Share | -$5.03 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 1.21B |
| Total Debt | 47.19M |
| Net Cash | 1.16B |
| Net Cash Per Share | $10.92 |
| Equity (Book Value) | 1.19B |
| Book Value Per Share | 11.27 |
| Working Capital | 1.16B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -422.52M |
| Capital Expenditures | -2.66M |
| Depreciation & Amortization | 4.24M |
| Net Borrowing | n/a |
| Free Cash Flow | -425.18M |
| FCF Per Share | -$4.01 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -1,302.52% |
| Pretax Margin | -1,189.45% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -11.25% |
| Shareholder Yield | n/a |
| Earnings Yield | -5.57% |
| FCF Yield | -4.72% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $85.00 |
| Price Target Difference | 0.06% |
| Analyst Consensus | Hold |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 284.78% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 16.07 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |